Schrödinger Announces the Release of FirstDiscovery 1.8
Schrödinger, Inc. is pleased to announce the general availability of version 1.8 of the FirstDiscovery suite, which contains breakthrough technologies designed to accelerate the drug discovery process and reduce overall costs. Leading pharmaceutical and drug discovery companies, including Bristol-Myers Squibb, Boehringer-Ingelheim, and Albany Molecular, have validated our solution and integrated it into their discovery processes for a distinct competitive advantage.
The unparalleled accuracy obtained using the FirstDiscovery suite complements and can greatly enhance current drug discovery efforts. Addressing some of the specific problems in experimental drug design, the FirstDiscovery suite:
reliably identifies lead compounds that meet stringent criteria early in the drug discovery process, supports experimental high-throughput screening (HTS), even when it is otherwise too expensive, too time consuming, or not available, increases the quality of candidates that proceed into lead optimization and development.
The FirstDiscovery suite includes Glide and QikProp, for high throughput library screening via binding affinity or pharmacokinetic properties, respectively. For lead optimization, FirstDiscovery includes Liaison, which elucidates contributions to binding affinity for drug candidates to within chemical accuracy, and QSite, which performs in-depth analysis of active-site chemistry. FirstDiscovery 1.8 is available for the SGI IRIX and PC Linux platforms.
Other news from the department research and development
